Compass Therapeutics (CMPX) Enterprise Value (2023 - 2025)
Historic Enterprise Value for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to -$220.5 million.
- Compass Therapeutics' Enterprise Value fell 6214.09% to -$220.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$220.5 million, marking a year-over-year decrease of 6214.09%. This contributed to the annual value of -$127.3 million for FY2024, which is 1650.98% up from last year.
- As of Q3 2025, Compass Therapeutics' Enterprise Value stood at -$220.5 million, which was down 6214.09% from -$101.5 million recorded in Q2 2025.
- Over the past 5 years, Compass Therapeutics' Enterprise Value peaked at -$101.5 million during Q2 2025, and registered a low of -$220.5 million during Q3 2025.
- Its 3-year average for Enterprise Value is -$152.8 million, with a median of -$152.5 million in 2023.
- Over the last 5 years, Compass Therapeutics' Enterprise Value had its largest YoY gain of 3570.35% in 2025, and its largest YoY loss of 6214.09% in 2025.
- Compass Therapeutics' Enterprise Value (Quarter) stood at -$152.5 million in 2023, then rose by 16.51% to -$127.3 million in 2024, then crashed by 73.2% to -$220.5 million in 2025.
- Its Enterprise Value was -$220.5 million in Q3 2025, compared to -$101.5 million in Q2 2025 and -$113.2 million in Q1 2025.